Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171145 · ClinicalTrials.gov registry record · Phase 3
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
A Phase 3 study of Overactive Bladder Syndrome, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
- 1
- Study location
NCT00171145: Completed Phase 3 study of Overactive Bladder Syndrome, sponsored by Novartis.
NCT00171145 is a Phase 3 study of Overactive Bladder Syndrome that has completed, run by Novartis. The registered enrollment target is 445 participants, above the 81-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (449% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00171145, a Phase 3 study of Overactive Bladder Syndrome, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Darifenacin
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
What the finished NCT00171145 record still lists
NCT00171145 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (449% higher).
The record links to 1 condition, with Overactive Bladder Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00171145 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00171145 about?
NCT00171145 is a clinical study titled "A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.". This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
What is the current status of trial NCT00171145?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2004-04. Estimated completion is 2004-12.
What conditions does trial NCT00171145 study?
This clinical trial studies the following conditions: Overactive Bladder Syndrome.
What interventions are being tested in trial NCT00171145?
The interventions under investigation include: Placebo (DRUG), Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00171145?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171145 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00171145's enrollment target sits among peer trials
445 1st of 11 higher than 11 of 11 other Overactive Bladder Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxybutynin for Post-surgical Bladder Pain and Urgency
RECRUITING · Phase 3
-
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
COMPLETED · Phase 3
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia